Under the terms of this agreement Tepnel has been appointed as a preferred supplier to AstraZeneca for DNA extraction services.
By continuing to provide a high quality service in the market Tepnel will have the opportunity to compete for further business and AstraZeneca will benefit from volume-related discounts.
Ben Matzilevich, CEO, commented, "Following our recent positive preliminary financial results for 2005 we are delighted at being able to announce more good news."
"AstraZeneca is already a valued client that has been working with us for a number of years and this agreement is proof of the high level of client service and technical expertise that we are able to deliver."
"This agreement further strengthens Tepnel’s position in the pharmaceutical industry as one of Europe’s largest providers of DNA extraction services."